Ozer, I. S. Et Al. 2021. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions. Clinical Neurology and Neurosurgery , vol.209 .

Ozer, I. S., Kuzu Kumcu, M., Tezcan Aydemir, S., & AKBOSTANCI, M. C., (2021). Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions. Clinical Neurology and Neurosurgery , vol.209.

Ozer, Incı Et Al. "Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions," Clinical Neurology and Neurosurgery , vol.209, 2021

Ozer, Incı S. Et Al. "Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions." Clinical Neurology and Neurosurgery , vol.209, 2021

Ozer, I. S. Et Al. (2021) . "Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions." Clinical Neurology and Neurosurgery , vol.209.

@article{article, author={Incı Sule Ozer Et Al. }, title={Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions}, journal={Clinical Neurology and Neurosurgery}, year=2021}